Intravenous glycoprotein IIbIIIa inhibitor (Tirofiban) combined with low dose of intra-arterial Urokinase for the endovascolar treatment of patients with acute major ischemic stroke.

Trial Profile

Intravenous glycoprotein IIbIIIa inhibitor (Tirofiban) combined with low dose of intra-arterial Urokinase for the endovascolar treatment of patients with acute major ischemic stroke.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2013

At a glance

  • Drugs Tirofiban (Primary) ; Urokinase
  • Indications Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Dec 2013 Last checked against European Clinical Trials Database record.
    • 14 Dec 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 01 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top